CA2797133C – August 6, 2019 – PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE

Please complete the required fields.




Inventors :

NEERUP, TRINE SKOVLUND RYGE; OSTERLUND, TORBEN; TOLBORG, JAKOB LIND; FOSGERAU, KELD; MARTENSSON, ULRIKA; BRORSON, MARIANNE; ROLSTED, KAMILLA

Owner :

ZEALAND PHARMA A/S

Application Number :

CA2797133

Document Number :

CA2797133C

Priority Date :

January 1, 1970

Filing Date :

April 27, 2011

Date of Grant/ Publication :

August 6, 2019

Class :

C07K14 / 575; A61K38 / 22; C07K14 / 595; C07K19 / 00

Abstract

The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.

Claim(s)

1. A peptide conjugate having the formula I RI-Z-L-Y-R2 (I) wherein R1 is H, C1 _4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R2 is OH or NH2 ; Z comprises the sequence of Exendin-4(1-39)having the sequence His – GlyGlu – GlyThrPheThrSerAspLeu – SerLys – Gin – MetGlu – Glu – Glu – AlaVal – Arg – Leu – Phelie – Glu – TrpLeu – Lys – Asn – GlyGlyProSerSerGlyAlaPro – ProPro – Ser or an analogue thereof Za; L is an optional linker moiety; and Y comprises the sequence of Gastrin17 having the sequence GIn-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Y15-Asp-Phe wherein Y15 is selected from Leu, Nie, Phe and Thr or an analogue thereof Ya.;
2. A peptide conjugate according to claim 1, wherein: (i) Z has substitutions in up to 10 positions, and/or comprises a C-terminal truncation of 1 to 12 amino acids, with respect to the sequence of Exendin-4; and/or (ii) Y has substitutions in up to 5 positions with respect to the sequence of Gastrinl 7, and/or comprises an N-terminal truncation of 1 to 13 amino acids, with respect to the sequence of Gastrinl 7.;
3. A peptide conjugate according to claim 1 or 2, wherein WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Za is a peptide sequence having the formula Ila His-Z2-Z3-Gly-Thr-Phe-Thr-Ser-Z9-Z10-Z11-Z12-Z13-Z14-Glu-Z16-Z17-Z18 – Zl 9 – Z20 – Z21 – Z22 – Z23 – Z24 – Z25 – Z26 – Z27 – Z28 – Z29 – Z30 – Z31 – Z32 – Z33 – Z34 – Z35 – Z36 – Z37 – Z38 – Z39 (lla) wherein Z2 is selected from Gly, Ala, Ser, Aib, Thr, Leu and lie; Z3 is selected from Glu and Asp; Z9 is selected from Asp and Glu; Zl0 is selected from Leu, Val, lie and Ala; Zl 1 is selected from Ser and Aib; Z12 is selected from Ser, Gin, Arg, Cys, Lys, Glu and Orn; Z13 is selected from Arg, Ser, Gin, Tyr and Glu; Z14 is selected from Gly, Cys, Phe, Tyr, Trp, Lys, Met, Leu, Nie and lie; Z16 is selected from Asp, Gly, Aib, Glu, Lys and Cys; Z17 is selected from Glu, Cys, Lys, Ser and Gin; Z18 is selected from Ala and Aib; Z19 is selected from Val, Leu, lie and Ala; Z20 is selected from Arg, Lys, Cys, Orn and Glu; Z21 is selected from Leu and Glu; Z22 is selected from Phe and Ala; Z23 is selected from lie and Leu; Z24 is selected from Glu, Cys, Lys, Ala and Arg; Z25 is selected from Trp, Cys, Lys and Phe; Z26 is selected from Leu and lie; Z27 is selected from lie, Val, Gin, Lys, Cys, Arg and Orn; Z28 is selected from Asn, Ser, Asp, Aib, Gin, Lys, Cys, Arg, Tyr, bAla, Glu, Orn and Leu or is absent; Z29 is selected from Gly, Aib and bAla or is absent; WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Z30 is selected from Gly, Cys, Lys and Arg or is absent; Z31 is selected from Pro, Ser and Asp or is absent; Z32 is selected from Ser and Lys or is absent; Z33 is Ser or is absent; Z34 is selected from Gly and Lys or is absent; Z35 is Ala or is absent; Z36 is Pro or is absent; Z37 is Pro or is absent; Z38 is Pro or is absent; Z39 is Ser or is absent; L is a peptide sequence having the formula lib L1-L2-L3-L4 (lib) wherein L1 is selected from Ser, Ala, Lys, Orn, bAla, 8Aoc, DBF, Peg3, Cys and Gin or is absent; L2 is selected from Ser, Ala, Lys, Orn, bAla, 8Aoc, DBF, Peg3, Cys and Gin or is absent; L3 is selected from Ser, Ala, Lys, ©rn, bAla, 8Aoc, DBF, Peg3, Cys and Gin or is absent; L4 is selected from Ser, Ala, Lys, Orn, bAla, 8Aoc, DBF, Peg3, Cys and Gin or is absent; Ya is a peptide sequence having the formula IIc Y1 -Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11 -Y12-Y13-Y14-Y15-Asp-Y17 (llc) wherein Y1 is Gin or is absent; Y2 is Gly or is absent; Y3 is Pro or is absent; Y4 is Trp or is absent; WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Y5 is Leu or is absent; Y6 is Glu or is absent; Y7 is Glu or is absent; Y8 is Glu or is absent; Y9 is Glu or is absent; Y10 is Glu or is absent; Y11 is Ala or is absent; Y12 is selected from Ala and Tyr or is absent; Y13 is selected from Gly and Ala or is absent; Y14 is selected from Trp, Phe, 1Nal and Met; Y15 is selected from Leu, Nie, Phe and Thr; and Y17 is selected from Phe and 3-(3-Pyridyl)-alanine.;
4. A peptide conjugate according to any one of claims 1-3 wherein Zais a peptide sequence having the formula Ilia His-Gly-Glu-Gly-Th rP he-Th r-Ser-Z9-Leu-Ser-Zl 2-Zl 3-Zl 4-Glu-Z16-Glu-Ala-Val-Z20-LeuPhe-Ile-Z24Z25-Leu-Z27-Z28 (l I la) wherein Z9 is selected from Asp and Glu; Z12 is selected from Lys, Arg and Orn; Z13 is selected from Gin and Tyr; Z14 is selected from Met and Leu; Z16 is selected from Glu, Cys and Lys; Z20 is selected from Arg, Lys and Orn; Z24 is selected from Lys and Glu; Z25 is selected from Trp, Lys, Cys and Phe; Z27 is selected from Lys, Arg and Orn; WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Z28 is selected from Asn and Asp or is absent; L is a peptide sequence having the formula IIIb L1-L2-L3-L4 (lllb) wherein L1 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L2 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L3 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L4 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; Yais a peptide sequence having the formula IIIc Y12-Y13-Y14-Y15-Asp-Y17 (lllc) wherein Y12 is selected from Tyr and Ala or is absent; Y13 is selected from Gly and Ala or is absent; Y14 is selected from Trp, 1Nal and Phe; Y15 is selected from Leu, Nie, Thr and Phe.; and Y17 is selected from Phe and 3-(3-Pyridyl)-alanine.;
5. A peptide conjugate according to any one of the claims 1-4 wherein Za is a peptide sequence having the formula IVa His-Gly-Glu-Gly-Th rP he-Th r-Ser-Z9-Leu-Ser-Zl 2-GinMet-Glu-Z16-Glu-Ala-VaI-Arg-LeuPh e-Ile-GluTrp-Leu-Z27-Z28 (IVa) wherein Z9 is selected from Glu and Asp; WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Z12 is selected from Lys and Orn; Z16 is selected from Glu and Lys; Z27 is selected from Lys and Orn; Z28 is selected from Asn and Asp or is absent; L is a peptide sequence having the formula IVb L1-L2-L3-L4 (IVb) wherein L1 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L2 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L3 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L4 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; Ya is a peptide sequence having the formula IVc Y12-Y13-Trp-Leu-Asp-Phe (IVc) wherein Y12 is Tyr or is absent; and Y13 is Gly or is absent.;
6. A peptide conjugate according to any one of the claims 1-5 wherein Za is a peptide sequence having the formula Va His-Gly-Glu-Gly-Th rP he-Th r-Ser-Z9-Leu-Ser-Zl 2-TyrLeu-Glu-Z16-Glu-Ala-VaI-Arg-LeuPheIle-GluPhe-Leu-Z27-Z28 (Va) wherein Z9 is selected from Glu and Asp; Z12 is selected from Lys and Orn; WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Z16 is selected from Glu and Lys; Z27 is selected from Lys and Orn; Z28 is selected from Asn and Asp or is absent; L is a peptide sequence having the formula Vb L1-L2-L3-L4 (Vb) wherein L1 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L2 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L3 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L4 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; Ya is a peptide sequence having the formula Vc Y12-Y13-Trp-Leu-Asp-Phe (Vc) wherein Y12 is Tyr or is absent; and Y13 is Gly or is absent.;
7. A peptide conjugate according to any one of the preceding claims wherein the peptide sequence of formula comprises one or more intramolecular bridges.;
8. A peptide conjugate according to claim 7 wherein said intramolecular bridge is formed between the side chains of two amino acid residues which are separated by three amino acids in the linear amino acid sequence of formula I. WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
9. A peptide conjugate according to claim 8 wherein the intramolecular bridge is formed between the side chains of residue pairs x and x+3, x+4 or x+5.;
10. A peptide conjugate according to any one of claims 7 to 9 wherein the intramolecular bridge is a lactam ring.;
11. A peptide conjugate according to any one of claims 7 to 10 wherein the intramolecular bridge involves a pair of residues wherein: Z12 is Lys and Z16 is Glu; Z12 is Glu and Z16 is Lys; Z16 is Glu and Z20 is Lys; Z16 is Lys and Z20 is Glu; Z20 is Glu and Z24 is Lys; Z20 is Lys and Z24 is Glu;;
claim 12: 12. A peptide conjugate according to any one of claims 1-11 wherein Za has at least 75% identity to native exendin-4, e.g. at least 80, 85, 90 or 95%.;
claim 13: 13. A peptide conjugate according to any one of claims 1-11 wherein Ya has at least 70% identity to native gastrin, e.g. at least 75, 80, 85, 90 or 95%. 14. formula A peptide conjugate according to any one of the preceding claims wherein the peptide of I has the sequence: Exend in-4(1-39)- Peg3Peg3-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-39)-[Gin 1, Leu 15]Gastrin 17, Exend in-4(1-39)-K-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-39)-AAA-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-39)-SKK-[GIn1 ,Leu15]Gastrin 17, Exend in-4(1-39)- Peg3-SKK-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-39)-8Aoc-SKK-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-39)-D BF-SKK-[GIn 1, Leu 15]Gastrin17, Exend in-4(1-39)-8Aoc-8Aoc-[GIn 1 ,Leu15]Gastrin 17, WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Exendin-4(1-39)-[Leu4]Gastrin6, Exendin-4(1-39)-K-[Leu4]Gastrin6, Exendin-4(1-39)-AAA-[Leu4]Gastrin6, Exendin-4(1-39)-SKK-[Leu4]Gastrin6, Exendin-4(1-39)-Peg3-SKK-[Leu4]Gastrin6, Exendin-4(1-39)-Peg3-Peg3-[Leu4]Gastrin6, Exendin-4(1-39)-8Aoc-SKK-[Leu4]Gastrin6, Exendin-4(1-39)-DBF-SKK-[Leu4]Gastrin6, Exendin-4(1-39)-8Aoc-8Aoc-[Leu4]Gastrin6, Exend in-4(1-28)-[Gin 1 ,Leu 15]Gastrin 17, Exend in-4(1-28)-K-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-28)-AAA-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-28)-S KK-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-28)- Peg3-SKK-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-28)- Peg3Peg3-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-28)-8Aoc-SKK-[GIn 1 ,Leu15]Gastrin 17, Exend in-4(1-28)-D BF-SKK-[GIn 1, Leu 15]Gastrin17, Exend in-4(1-28)-8Aoc-8Aoc-[GIn 1 ,Leu15]Gastrin 17, Exendin-4(1-28)-[Leu4]Gastrin6, Exendin-4(1-28)-K-[Leu4]Gastrin6, Exendin-4(1-28)-AAA-[Leu4]Gastrin6, Exendin-4(1-28)-SKK-[Leu4]Gastrin6, Exendin-4(1-28)-Peg3-SKK-[Leu4]Gastrin6, Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6, Exendin-4(1-28)-8Aoc-SKK-[Leu4]Gastrin6, Exendin-4(1-28)-DBF-SKK-[Leu4]Gastrin6, Exendin-4(1-28)-8Aoc-8Aoc-[Leu4]Gastrin6, or a pharmaceutically acceptable sait or solvate thereof. WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
claim 14: 15. A peptide conjugate according to claims 1 to 11 wherein the peptide of formula I has the sequence: Exendin-4(1-28)-Peg3-Peg3-[Leu3]Gastrin5 Exend in-4(1-28)-Peg3-Peg3-[Alal, Leu4]Gastrin6 Exendin-4(1-28)-Peg3-Peg3-[Ala2, Leu4]Gastrin6 Exendin-4(1-27)-Peg3-Peg3-[Leu4]Gastrin6 Exendin-4(1-28)-Peg3-Peg3-[Leu2]Gastrin4 [Leu14] Exendin-4(1-28)- Peg3Peg3-[Leu4]Gastrin6 [Orn 12]Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6 [Orn27]Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6 [Phe25] Exendin-4(1-28)- Peg3Peg3-[Leu4]Gastrin6 [Asp28]Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6 [Tyr13]Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6 [Orn20] Exendin-4(1-28)- Peg3Peg3-[Leu4]Gastrin6 Exendin-4(1-28)-Peg3-[Leu4]Gastrin6 Exendin-4(1-28)-[Leu4]Gastrin6 Exend in-4(1-27)-[Leu4]Gastrin 11 Exendin-4(1-27)-Peg3-[Leu4]Gastrin6 Exendin-4(1-27)-Peg3-[Leu3]Gastrin5 Exendin-4(1-26)-Peg3-[Leu3]Gastrin5 Exendin-4(1-27)-Peg3-[Leu2]Gastrin4 [Tyr13,Leu14]Exendin-4(1-27)-Peg3-Peg3-[Leu4]Gastrin6 [Tyr 13, Phe25]Exendin-4(1-27)- Peg3-Peg3-[Leu4]Gastrin6 [Leu 14, Phe25]Exendin-4(1-27)-Peg3-Peg3-[Leu4]Gastrin6 [Tyrl 3,Leu14, Phe25]Exendin-4(1-27)- Peg3-Peg3-[Leu4]Gastrin6 Side chain-cyclo([Lys12,Glu16]Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6 Side chain-cyclo([Glu 16,Lys20]Exendin-4(1-28)-Peg3Peg3-[Leu4]Gastrin6 Side chain-cyclo([Lys20,Glu24]Exendin-4(1-28)-Peg3-Peg3-[Leu4]Gastrin6 WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Glu9,Leu 14, Phe25,Tyr1 [Lys16] Exendin-4(1-28)- Peg3Peg3-[Leu4]Gastrin6 Exendin-4(1-28)-Peg3-K-Peg3-[Leu4]Gastrin6 Exendin-4(1-28)-[Thr4]Gastrin6 Exendin-4(1-28)-[Phe4]Gastrin6 [Leu14]Exendin-4(1-28)-[1Nal3, Leu4]Gastrin6 [Leu14] Exendin-4(1-28)-[Nle4]Gastrin6 [Leu14] Exendin-4(1-28)-[Le u4, [3-(3Pyridyl)-Ala]6]G ast ri n6 [Glu9, Leu 14, Phe25,Tyr 13] Exendin-4(1-27)- Peg3Peg3-[Leu4]Gastrin6 [Leu 14, Phe25,Tyr13]Exendin-4(1-27)- Peg3-Peg3-[Leu4, Phe3]Gastrin6 [Glu9, Leu 14, Phe25,Tyr 13] Exendin-4(1-27)- Peg3Peg3-[Leu4, Phe3]Gastrin6 [Arg27, Leu 14, P he25,Tyr 13] Exendin-4(1-27)- Peg3-[Leu4]Gastrin6 [Argl 2,27, Leu 14, Lys 16, Ph e25,Tyr 13] Exendin-4(1-27)- Peg3-[Leu4]Gastrin6 [Argl 2,27, Leu 14, Lys20, Ph e25,Tyr 13] Exendin-4(1-27)- Peg3-[Leu4]Gastrin6 [Argl 2,27, Leu 14, Lys24, Ph e25,Tyr 13] Exendin-4(1-27)- Peg3-[Leu4]Gastrin6 [Argl 2, Leu 14, P he25,Tyr 13] Exendin-4(1-27)- Peg3-[Leu4]Gastrin6 [Glu9, Leu 14, Phe25,Tyr 13] Exendin-4(1-27)-[Le u2]Gastrin4 3]Exendin-4(1-27)-Peg3-[Leu2]Gastrin4 3]Exendin-4(1-27)-OrnPeg3-[Leu2]Gastrin4 3]Exendin-4(1-27)-Peg3-Orn-[Leu2]Gastrin4 3]Exendin-4(1-27)-Orn-Orn-[Leu2]Gastrin4 3]Exendin-4(1-27)-[Leu4]Gastrin6 3]Exendin-4(1-27)-Peg3-[Leu4]Gastrin6 3]Exendin-4(1-27)-OrnPeg3-[Leu4]Gastrin6 3]Exendin-4(1-27)-Peg3-Orn-[Leu4]Gastrin6 [Glu9, Leu 14, Phe25,Tyr 13] Exendin-4(1-27)-Orn-Orn-[Le u4]Gastrin6 or a pharmaceutically acceptable sait or solvate thereof. WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
claim 15: 16. A peptide conjugate having the formula Vl: RI-X-L-Y-R2 (Vl) wherein R1 is H, C1 _4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R2 is OH or NH2 ; X comprises the sequence of GLP-1 (7-36) having the sequence HisAlaGlu – GlyThr – Phe – ThrSer – Asp – Val – Ser – SerTyr-Leu – Glu – GlyGin – AlaAla – LysGlu-Phe – lieAlaTrp – Leu – ValLys – Gly-Arg or an analogue thereof Xa; L is a linker containing up to 4 naturally or non-naturally amino acids or combinations thereof or is absent; Y comprises the sequence of Gastrin-17 having the sequence GIn-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Y15-Asp-Phe wherein Y15 is selected from Leu, Nie, Phe and Thr or an analogue thereof Ya. 17. A peptide conjugate according to claim 16, wherein: (i) X has substitutions in up to 5 positions and/or comprises a C-terminally truncation of 1-2 amino acids, with respect to the sequence of GLP-1 ; and/or (ii) Y has substitutions in up to 5 positions with respect to the sequence of Gastrinl 7, and/or comprises an N-terminal truncation of 1 to 13 amino acids, with respect to the sequence of Gastrinl 7.;
claim 16: 18. A peptide conjugate according to any one of claims 16-17 wherein X is a peptide sequence having the formula Vlla HisX8 – Glu – GlyThrPhe – ThrSer – Asp – Val – SerSer – Tyr-Leu – Glu – GlyGin – AlaAla -X26Glu-Phelie – AlaTrp – Leu – Val-X34 – Gly-X36 (Vlla) wherein WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 X8 is selected from Ala, Aib and Gly; X26 is selected from Arg and Lys; X34 is selected from Arg and Lys; X36 is selected from Arg and Lys; L is a peptide sequence having the formula VIIb L1-L2-L3-L4 (VIIb) wherein L1 is selected from Ser, Ala, Lys, Orn, L2 is selected from Ser, Ala, Lys, Orn, L3 is selected from Ser, Ala, Lys, Orn, bAla, 8Aoc, DBF, Peg3, Cys, Gin or is absent; bAla, 8Aoc, DBF, Peg3, Cys, Gin or is absent; bAla, 8Aoc, DBF, Peg3, Cys, Gin or is absent; L4 is selected from Ser, Ala, Lys, Orn, bAla, 8Aoc, DBF, Peg3, Cys, Gin or is absent; Ya is a peptide sequence having the formula VIIc Y1 -Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11 -Y12-Y13-Y14-Y15-Asp-Y17 (VIIc) wherein Y1 is Gin or is absent; Y2 is Gly or is absent; Y3 is Pro or is absent; Y4 is Trp or is absent; Y5 is Leu or is absent; Y6 is Glu or is absent; Y7 is Glu or is absent; Y8 is Glu or is absent; Y9 is Glu or is absent; Y10 is Glu or is absent; WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 Y11 is Ala or is absent; Y12 is selected from Ala, Tyr or is absent; Y13 is selected from Gly, Ala or is absent; Y14 is selected from Trp, Phe, 1Nal and Met; Y15 is selected from Leu, Nie, Phe and Thr: and Y17 is selected from Phe and 3-(3-Pyridyl)-alanine.;
claim 17: 19. A peptide conjugate according to any one of claims 16-18 wherein Xa is a peptide sequence having the formula Villa HisX8 – Glu – GlyThrPhe – ThrSer – Asp – Val – SerSer – Tyr-Leu – Glu – GlyGin – AlaAla -X26Glu-Phelie – AlaTrp – Leu – Val-X34 – Gly-X36 (Villa) wherein X8 is selected from Ala, Aib and Gly; X26 is selected from Arg and Lys; X34 is selected from Arg and Lys; X36 is selected from Arg and Lys; L is a peptide sequence having the formula VIIIb L1-L2-L3-L4 (Vlllb) wherein L1 is selected from Peg3, Orn, Cys, Lys, Gin or is absent; L2 is selected from Ser, Ala, Orn, Cys, Lys, Gin or is absent; L3 is selected from Lys, Ala, Cys, Orn, Gin or is absent; L4 is selected from Lys, Orn, Ala, Peg3, Cys, Lys, Gin or is absent; Ya is a peptide sequence having the formula VIIIc Y12-Y13-Y14-Y15-Asp-Phe (Vlllc) WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 wherein Y12 is selected from Tyr, Ala or is absent; Y13 is selected from Gly, Ala or is absent; Y14 is selected from Trp and Phe; and Y15 is selected from Leu, Thr and Phe.;
claim 18: 20. A peptide conjugate according to any one of claims 16-19 wherein Xa is a peptide sequence having the formula IXa HisX8 – Glu – GlyThrPhe – ThrSer – Asp – Val – SerSer – Tyr-Leu – Glu – GlyGin – AlaAla – X26 – Glu -Phe – lie – Ala – Trp – Leu – Val – X34 – Gly – X36 (IXa) wherein X8 is selected from Ala, Aib and Gly; X26 is selected from Arg and Lys; X34 is selected from Arg and Lys; X36 is selected from Arg and Lys; L is a peptide sequence having the formula IXb L1-L2-L3 (IXb) wherein L1 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L2 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L3 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; L4 is selected from Peg3, Gin, Cys, Lys and Orn or is absent; Ya is a peptide sequence having the formula IXc Y12-Y13-Trp-Leu-Asp-Phe (IXc) WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 wherein Y12 is Tyr or is absent; and Y13 is Gly or is absent.;
claim 19: 21. A peptide conjugate according to any one of claims 16-20 wherein Xa has at least 85% identity to native exendin-4, e.g. at least 90, 95, 97, 98, 99 or 99.5%.;
claim 20: 22. A peptide conjugate according to any one of claims 16-21, wherein at least one Lys or Cys is further conjugated to a lipophilic substituent.;
claim 21: 23. A peptide conjugate according to any one of claims 16-21 wherein the peptide of formula Vl has the sequence: GLP-1 (7-36)-[Gin 1, Leu15]Gastrin 17, GLP-1 (7-36)-K-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)-AAA-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)-SKK-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)- Peg3-SKK-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)- Peg3Peg3-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)-8Aoc-S KK-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)- D BF-SKK-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)-8Aoc-8Aoc-[GIn 1 ,Leu15]Gastrin 17, GLP-1 (7-36)-[Leu4]Gastrin6, GLP-1 (7-36)-K-[Leu4]Gastrin6, GLP-1 (7-36)-AAA-[Leu4]Gastrin6, GLP-1 (7-36)-SKK-[Leu4]Gastrin6, GLP-1 (7-36)-Peg3-SKK-[Leu4]Gastrin6, GLP-1 (7-36)-Peg3-Peg3-[Leu4]Gastrin6, GLP-1 (7-36)-8Aoc-S KK-[Le u4]Gastrin6, WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133 GLP-1 (7-36)-DBF-SKK-[Leu4]Gastrin6 GLP-1 (7-36)-8Aoc-8Aoc-[Leu4]Gastrin6, [Aib8,Arg34]GLP-1 (7-37)- Peg3-Peg3-[Leu4]Gastrin6 [Arg34]GLP-1 (7-37)-Peg3-Peg3-[Leu4]Gastrin6 or a pharmaceutically acceptable sait or solvate thereof.;
claim 22: 24. A peptide conjugate according to any one of the claims 16 to 22 wherein the peptide of formula Vl has the sequence: [Lys(Hexadecanoyl-isoGlu)34]GLP-1 (7-37)-Peg3Peg3-[Leu4]Gastrin6, [Arg34, Lys(H exadecanoyl-isoGlu)26]G LP1 (7-37)- Peg3Peg3-[Leu4]Gastrin6 [Arg26,34,Lys(Hexadecanoyl-isoGlu)36]GLP-1 (7-37)- Peg3-Peg3-[Leu4]Gastrin6 [Lys(Hexadecanoyl-isoGlu)26]GLP-1 (7-37)-Peg3-Peg3-[Leu4]Gastrin6 [Arg26,34,Gly8,Lys(Hexadecanoyl-isoGlu)36]GLP1 (7-37)-Peg3Peg3-[Leu4]Gastrin6 [Aib8,Arg34,Lys(Hexadecanoyl-isoGlu)26]GLP-1 (7-37)-Peg3-Peg3-[Leu4]Gastrin6 or a pharmaceutically acceptable sait or solvate thereof.;
claim 23: 25. A peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to claim 1 to 24, for use as a medicament.;
claim 24: 26. A peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to claim 25, for use as a medicament for the treatment, in a subject in need thereof, of a disease or disorder selected from the group consisting of: type 1 diabetes, type 2 diabetes, pre-diabetes, Insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, hyperglycemia, hypertension, atherogenic dyslipidemia, arteriosclerosis (e.g. atherosclerosis), coronary heart disease, peripheral artery disease, stroke, microvascular disease, gastric disease, metabolic syndrome, cancer (e.g. colon cancer), inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
claim 25: 27. A peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to claim 25, for use as a medicament for inducing, in a subject in need thereof, pancreatic islet neogenesis.;
claim 26: 28. A peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to claim 25, for use as a medicament for preventing, in a subject in need thereof, 13-cell apoptosis in the pancreatic islets.;
claim 27: 29. A peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to any one of claims 25-28, wherein said subject is a human.;
claim 28: 30. A method for treatment, in a subject in need thereof, of a disease or disorder selected from the group consisting of: type 1 diabetes, type 2 diabetes, pre-diabetes, Insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, hyperglycemia, hypertension, atherogenic dyslipidemia, arteriosclerosis (e.g. atherosclerosis), coronary heart disease, peripheral artery disease, stroke, microvascular disease, gastric disease, metabolic syndrome, cancer (e.g. colon cancer), inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), the method comprising administering to said subject a therapeutically effective amount of a peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to claim 1 to 29.;
claim 29: 31. A method according to claim 30, wherein said subject is a human.;
claim 30: 32. A pharmaceutical composition comprising a peptide conjugate, or pharmaceutically acceptable sait or solvate thereof, according to claim 1 to 29, together with a pharmaceutically acceptable carrier, excipient or vehicle. WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
claim 31: 33. A pharmaceutical composition according to claim 32 for use in preventing weight gain or promoting weight loss.;
claim 32: 34. A compound according to any one of claims 1 to 29 for use in a method of improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio.;
claim 33: 35. A compound according to any one of claims 1 to 29 for use in a method of treatment of a condition caused or characterized by excess body weight, e.g. the treatment and/or prevention of obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, metabolic syndrome, pre-diabetes, the method comprising administering to said subject a therapeutically effective amount of a peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to any one of claims 1 to 29.;
claim 34: 36. Use of a compound according to any one of claims 1 to 29 for preventing weight gain or promoting weight loss in an individual in need thereof.;
claim 35: 37. Use of a compound according to any one of claims 1 to 29 in a method of improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio in an individual in need thereof.;
claim 36: 38. A compound, use or method according to any one of claims 1 to 37 wherein the compound is administered as part of a combination therapy with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension.;
claim 37: 39. A compound, use or method according to claim 38 wherein the agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or an insulin analogue. WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
claim 38: 40. A compound, use or method according to claim 38 wherein the agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist.;
claim 39: 41. A compound, use or method according to claim 38 wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker.;
claim 40: 42. A compound, use or method according to claim 38 wherein the agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin and/or a cholesterol absorbtion inhibitor. 43 A method of manufacturing a peptide conjugate according to any one of claims 1 to 24 synthetically.;
claim 41: 44. A method of manufacturing a peptide conjugate according to any one of claims 1 to 24 recombinantly.;
claim 42: 45. Use of a compound according to any one of claims 1 to 24 in a method of improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio in an individual in need thereof wherein a Drug holiday dosage regimen is used.;
claim 43: 46. A process for manufacturing a compound according to any of the above claims.;
claim 44: 47. A pharmaceutical composition comprising a peptide conjugate, or pharmaceutically acceptable sait or solvate thereof, according to claim 1 to 29, in combination with one or more peptide conjugate or pharmaceutically acceptable sait or solvate thereof according to claim 1 to 29 together with a pharmaceutically acceptable carrier, excipient or vehicle.;
claim 45: 48. A device comprising at least one peptide conjugate, or pharmaceutically acceptable sait or solvate thereof, according to claim 1 to 29, for delivery of the peptide conjugate to a subject. WO 2011/134471 CA 02797133 2012-10-23 PCT/DK2011/050133;
claim 46: 49. A kit comprising at least one peptide conjugate, or pharmaceutically acceptable sait or solvate thereof, according to claim 1 to 29, and further comprising packaging or instructions for use.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login